| Rights Issue Size | ₹900.00 CrBoard Limit |
|---|---|
| Market Cap | ₹4,955.32 CrPharmaceuticals |
| P/E TTM | 50.68Sector 47.26 |
| 1-Year Return | 129.42%Price Performance |
| Deal value | ₹900 Cr |
| Share of market cap | 18.2% |
Key highlights
- Rights issue of up to ₹9,000 million approved for eligible equity shareholders
- Issuance involves partly paid-up equity shares with a face value of ₹5 each
- Fund raise follows the company's rebranding from Novartis India Limited to Evonile Pharma
- A dedicated Rights Issue Committee has been formed to finalize the issue price and ratio
- Proceeds arrive as management targets doubling revenue over the next four to five years
Capital Infusion Through Rights Mechanism
Evonile Pharma Limited has authorized the issuance and allotment of partly paid-up equity shares to raise a total aggregate amount not exceeding ₹900 crore. The rights issue is aimed at eligible equity shareholders as of a record date to be determined by a newly constituted committee. This fund-raising initiative is designed to strengthen the company’s balance sheet, which recently saw a significant cash outflow for the ₹1,250 crore acquisition of the Minipress trademark portfolio.
The shares carry a face value of ₹5 each, with the specific issue price and entitlement ratio pending finalization by the board-appointed committee.
Administrative and Growth Milestones
- Constitution of a Rights Issue Committee led by MD Vikas Gupta and Independent Director Shashank Sinha
- Approval of a Postal Ballot notice to obtain shareholder clearance for the proposed fund raise
- Official launch of the new corporate website under the domain evonilepharma.com
- The board meeting concluded at 5:31 PM IST on October 08, 2026, following a 51-minute session
- Rebranding from Novartis India Limited was completed to align with the company's independent growth path
Strategic Backdrop and Financial Profile
The proposed ₹900 crore raise lands on a balance sheet characterized by steady growth and high operating efficiency. For the quarter ended June 30, 2026, the company reported a net profit of ₹32.21 crore on operating revenue of ₹103.81 crore, reflecting a year-on-year revenue growth of 18.57%. Operating profit margins stood at 33.63%, an improvement over the 31.1% recorded four quarters prior.
This financial momentum supports management’s guidance from September 2026, which anticipates a doubling of revenue within the next five years and a sustained recovery of operating margins above the 20% threshold.
| Date | Announcement | Amount |
|---|---|---|
| 05 Oct 2026 | Rights issue of equity sharesSource: choiceindia.com | – |
What to watch next
- Board meeting scheduled for November 03, 2026, to approve Q2 and H1 FY27 financial results
- Finalization of the rights issue price and entitlement ratio by the Rights Issue Committee
- Announcement of the record date for shareholder eligibility for the rights offering
| Share price | ₹2006.95 |
|---|---|
| Market capitalisation | ₹4,955.32 Cr |
| Revenue (annual) | ₹354.33 Cr |
| Net profit (annual) | ₹93.18 Cr |
| Revenue (latest quarter) | ₹103.81 Cr+14.64% vs previous quarter |
| Net profit (latest quarter) | ₹32.21 Cr+27.56% vs previous quarter |
| P/E (TTM) | 50.68×Sector 47.26× |
| Promoter holding | 70.68%0.00% QoQ |
| FII holding | 0.15%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Evonile Pharma Limited announcing the board approval for a rights issue of up to ₹900 crore. Market figures from a third-party data provider.
Track Novartis India live
Get the next Novartis India filing on Telegram seconds after it lands. 15 days free.
